Pocket some grey pounds – three healthcare stocks to buy now

The ageing population is an opportunity for the health and medical sector. Here, professional investor Garry White picks three healthcare stocks to buy now.

Each week, aprofessional investor tells MoneyWeek where he'd put his money now. This week:Garry White, chief investment commentator, Charles Stanley.

Asset allocation matters more than individual stockpicking. So you must pay attention to trends across sectors and markets, to ensure you are well positioned for future moves. One of the biggest trends in the FTSE 100 this century was the rise and now fall of commodities. The weighting of commodity-related stocks in the index is now falling as Chinese growth stutters and supply moves into surplus, sending miners' share prices to multi-year lows. Oil companies are also being hit while oil-service companies such as Petrofac and Wood Group have already been demoted from the index. Another sector with a declining blue-chip weighting is engineers, with companies such as Melrose Industries demoted to the FTSE 250 and Weir Group a strong candidate to exit at next month's reshuffle.

Subscribe to MoneyWeek

Become a smarter, better informed investor with MoneyWeek.

But one sector healthcare looks very different. The global population is rising, ageing and gentrifying. As people get richer they tend to spend more on health and wellbeing. This is an opportunity for drugs groups, healthcare providers and medical device makers. Over the next few years, the healthcare component of the FTSE 100 is likely to grow. AstraZeneca and GlaxoSmithKline have endured significant pain over the last few years: blockbuster treatments have come off patent and new discoveries have been few and far between. However, they now seem to be over the worst. Shire has ambitious, acquisitive plans and Hikma Pharmaceuticals, which entered the FTSE 100 in March, is also likely to grow by acquisition. In the FTSE 250, NMC Health, the largest healthcare provider in the United Arab Emirates, and Abu Dhabi-based Al-Noor Hospitals are also growing fast.

One way to play the rise of healthcare provision in emerging markets is via an exchange-traded fund (ETF). The db x-trackers MSCI EM Healthcare fund (LSE: XMEH) tracks the emerging-markets healthcare sector. A company's weighting in the index depends on its relative size based on the combined value of its readily available shares, compared to other companies. The index holds 30 equities across ten countries and has a dividend yield of 0.88%. The top ten holdings account for 60% of the ETF and the sector breakdown within this is 68% pharmaceuticals, 20% healthcare facilities, 6.7% healthcare distributors, 2.3% managed healthcare, 1% healthcare supplies and 1.3% life science tools and services.

Advertisement
Advertisement - Article continues below

Hikma (LSE: HIK) does not develop its own drugs, but makes generic copies of older medicines whose patent protection has expired. Its recent purchase of US specialist generics company Roxane from Germany's Boehringer Ingelheim for $2.65bn has transformed its position in the US market. Revenues in 2014 were up 9% and the company expects to meet the City's growth expectation this year.

In the past, Shire (LSE: SHP) has been accused of being too reliant on its best-selling treatment for attention deficit hyperactivity disorder (ADHD), Adderall XR. But Shire's current strategy involves expanding into high-profit margin niche treatments. These include treatments for conditions such as binge-eating disorder. Last year, Shire's revenues came in at around $6bn, but the company has recently made an unsolicited bid for recently listed US business Baxalta. Baxalta's board is yet to open its books and the offer is likely to be raised. Shire sees the deal as an opportunity to create a global leader in rare diseases, with product sales of about $20bn by 2020.

Advertisement

Recommended

Visit/investments/stocks-and-shares/share-tips/600641/share-tips-of-the-week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Jan 2020
Visit/519913/share-tips-8-stocks-for-robust-returns
Share tips

Share tips: eight stocks that should deliver robust returns

Ryan Ermey of US publication Kiplinger’s Personal Finance chooses his favourite stocks for the next decade, which should be able to grow for years.
28 Dec 2019
Visit/519724/share-tips-of-the-week-166
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 Dec 2019
Visit/519436/share-tips-of-the-week-165
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
13 Dec 2019

Most Popular

Visit/520525/currency-corner-how-high-can-the-pound-go-against-the-euro-in-2020
Currencies

Currency Corner: how high can the pound go against the euro in 2020?

In the month in which we should finally leave the European Union, Dominic Frisby takes a look at the pound vs the euro and asks just how high sterling…
13 Jan 2020
Visit/520553/money-minute-wednesday-15-january
Economy

Money Minute Wednesday 15 January: UK inflation and house prices

In today’s Money Minute, we look ahead to the latest UK inflation and house price figures, plus we have Germany’s GDP data for 2019.
15 Jan 2020
Visit/520598/money-minute-thursday-16-january-a-batch-of-company-results
Economy

Money Minute Thursday 16 January: a batch of company results

Today's Money Minute looks ahead to results from a host of UK companies, plus the latest unemployment figures from the US.
15 Jan 2020
Visit/520575/20-predictions-for-the-2020s
Investments

Where will markets be in 2030? Here are 20 forecasts for the 2020s

A lot has changed in the last ten years – stockmarkets soared, technology transformed our lives and politics has changed beyond measure. Here, Dominic…
14 Jan 2020